# EBS catalysts: Emergent BioSolutions Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ebs/catalysts

> Emergent BioSolutions Inc. (EBS) has no upcoming catalysts in this calendar. The latest recorded is the Emergent BioSolutions Inc. earnings report, November 2, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Emergent BioSolutions Inc. |
| Ticker | EBS (NYSE) |
| SEC CIK | 1367644 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ebs |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 15, 2023 | [NARCAN (narcan) FDA advisory committee meeting](https://sec-api.dev/pdufa/narcan) | EBS |  | completed, positive | "On February 15, 2023, the FDA Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee unanimously voted in favor (a total of 19 votes) that the benefit-risk profile of NARCAN® Nasal Spray was supportive of its use as a nonprescription opioid overdose reversal agent." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1367644/000136764425000021/ebs-20241231.htm)) |
| Jul 2023 | [CYFENDUS (AV7909) FDA approval](https://sec-api.dev/pdufa/av7909) | EBS |  | completed, approved | "CYFENDUS® was approved by the U.S. Food and Drug Administration in July 2023 as a two-dose anthrax vaccine for post-exposure prophylaxis use in individuals 18 through 65 years of age when given with recommended antibacterial drugs." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000088/a08182026contractmodpr.htm)) |
| Aug 2024 | [Emergent BioSolutions Inc. FDA approval](https://sec-api.dev/companies/ebs/catalysts) | EBS | smallpox disease in individuals determined | completed, approved | "The vaccine was first approved by the U.S. Food and Drug Administration (FDA) in 2007 for active immunization for the prevention of smallpox disease in individuals determined to be at high risk for smallpox infection, and was FDA approved in August 2024 for immunization against mpox in individuals determined to be at high-risk for mpox." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764425000188/a09092025acam2000pressrele.htm)) |
| March 3, 2025 | [Emergent BioSolutions Inc. earnings report](https://sec-api.dev/companies/ebs/catalysts) | EBS |  | completed | "EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764425000019/ebs2024-12x31ex99earningsr.htm)) |
| May 7, 2025 | [Emergent BioSolutions Inc. earnings report](https://sec-api.dev/companies/ebs/catalysts) | EBS |  | completed | "EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764425000121/ebs2025-03x31ex99earningsr.htm)) |
| August 6, 2025 | [Emergent BioSolutions Inc. earnings report](https://sec-api.dev/companies/ebs/catalysts) | EBS |  | completed | "EMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764425000179/ebs2025-06x30ex99earningsr.htm)) |
| October 29, 2025 | [Emergent BioSolutions Inc. earnings report](https://sec-api.dev/companies/ebs/catalysts) | EBS |  | completed | "EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764425000198/ebs2025-09x30ex99er.htm)) |
| December 12, 2025 | [Raxibacumab label expansion decision](https://sec-api.dev/pdufa/raxibacumab) | EBS |  | completed, approved | "GAITHERSBURG, Md., December 12, 2025 (GLOBE NEWSWIRE) - Emergent BioSolutions (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for its Winnipeg, Canada facility to be added as the drug product manufacturing and testing site for raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764425000207/a12122025raxi.htm)) |
| February 26, 2026 | [Emergent BioSolutions Inc. earnings report](https://sec-api.dev/companies/ebs/catalysts) | EBS |  | completed | "EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000012/ebs2025-12x31exhibit99er.htm)) |
| April 30, 2026 | [Emergent BioSolutions Inc. earnings report](https://sec-api.dev/companies/ebs/catalysts) | EBS |  | completed | "EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000059/ebs20260331ex99er.htm)) |
| August 5, 2026 | [Emergent BioSolutions Inc. earnings report](https://sec-api.dev/companies/ebs/catalysts) | EBS |  | completed | "EMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000080/ebs202606-30ex99er.htm)) |
| November 2, 2026 | [Emergent BioSolutions Inc. earnings report](https://sec-api.dev/companies/ebs/catalysts) | EBS |  | completed | "EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000110/ebs202609-30ex99er.htm)) |

## Drugs

- [CYFENDUS (AV7909)](https://sec-api.dev/pdufa/av7909): 
- [NARCAN (narcan)](https://sec-api.dev/pdufa/narcan): 
- [Raxibacumab](https://sec-api.dev/pdufa/raxibacumab): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ebs/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "EBS catalysts: Emergent BioSolutions Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ebs/catalysts

```bibtex
@misc{secapidev_companies_ebs_catalysts_20261116,
  title        = {EBS catalysts: Emergent BioSolutions Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ebs/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ebs_catalysts_20261116","title":"EBS catalysts: Emergent BioSolutions Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ebs/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
